Yttrium-90-labelled somatostatin-analogue for cancer treatment

被引:289
作者
Otte, A [1 ]
Mueller-Brand, J
Dellas, S
Nitzsche, EU
Herrmann, R
Maecke, HR
机构
[1] Univ Basel Hosp, Inst Nucl Med, Dept Med Radiol, CH-4031 Basel, Switzerland
[2] Univ Basel Hosp, Inst Nucl Med, Dept Oncol, CH-4031 Basel, Switzerland
[3] Univ Hosp, Dept Nucl Med, Freiburg, Germany
关键词
D O I
10.1016/S0140-6736(05)78355-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
[No abstract available]
引用
收藏
页码:417 / 418
页数:2
相关论文
共 4 条
[1]   Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA(0),D-Phe(1),Tyr(3)]octreotide, a promising somatostatin analogue for radionuclide therapy [J].
deJong, M ;
Bakker, WH ;
Krenning, EP ;
Breeman, WAP ;
vanderPluijm, ME ;
Bernard, BF ;
Visser, TJ ;
Jermann, E ;
Behe, M ;
Powell, P ;
Macke, HR .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1997, 24 (04) :368-371
[2]   Somatostatin receptor: Scintigraphy and radionuclide therapy [J].
Krenning, EP ;
Kooij, PPM ;
Pauwels, S ;
Breeman, WAP ;
Postema, PTE ;
DeHerder, WW ;
Valkema, R ;
Kwekkeboom, DJ .
DIGESTION, 1996, 57 :57-61
[3]   Drug therapy - Octreotide [J].
Lamberts, SWJ ;
vanderLely, AJ ;
deHerder, WW ;
Hofland, LJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (04) :246-254
[4]  
Otte A, 1997, EUR J NUCL MED, V24, P792